EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Natural products targeting tumour angiogenesis

Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth

British Journal of Pharmacology · 2025-05 · 182 (10) · 2094-2136

DOI: 10.1111/bph.16232 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-10-05. Written by Xiaohua Lu and 2 co-authors. Institution: Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Mainz, Germany. Major MEDLINE topics: Biological Products, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors. Cited 47 times so far (Crossref); 339 references. The full text is freely available (open access, CC BY 4.0). Funded by: Theophrastus Stiftung, Mühltal, Germany.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour growth and progression. In this review, we comprehensively report on the current status of natural products against tumour angiogenesis from four perspectives until March 2023: (1) the role of pro‐angiogenic factors and antiangiogenic factors in tumour angiogenesis; (2) the development of anti‐tumour angiogenesis therapy (monoclonal antibodies, VEGFR‐targeted small molecules and fusion proteins); (3) the summary of anti‐angiogenic natural agents, including polyphenols, polysaccharides, alkaloids, terpenoids, saponins and their mechanisms of action, and (4) the future perspectives of anti‐angiogenic natural products (bioavailability improvement, testing of dosage and side effects, combination use and discovery of unique natural‐based compounds). Our review aims to better understand the potential of natural products for drug development in inhibiting tumour angiogenesis and further aid the effective transition of these outcomes into clinical trials. LINKED ARTICLES This article is part of a themed issue Natural Products and Cancer: From Drug Discovery to Prevention and Therapy. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.10/issuetoc

Subjects

MeSH terms (MEDLINE)

Biological ProductsNeoplasmsNeovascularization, PathologicAngiogenesis InhibitorsHumansAnimalsAngiogenesis

Author keywords

VEGFR‐2 inhibitorsnatural productsphytochemicalstargeted chemotherapytumour angiogenesis

Substances

Biological ProductsAngiogenesis Inhibitors

Authors and institutions

  • Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Mainz, Germany.

Funding

  • Theophrastus Stiftung, Mühltal, Germany

Cite

APA

Lu, X., Friedrich, L. J., & Efferth, T. (2025). Natural products targeting tumour angiogenesis. British Journal of Pharmacology, 182(10), 2094-2136. https://doi.org/10.1111/bph.16232

Vancouver

Lu X, Friedrich LJ, Efferth T. Natural products targeting tumour angiogenesis. British Journal of Pharmacology. 2025;182(10):2094-2136. doi:10.1111/bph.16232

BibTeX
@article{Lu2025,
  author = {Lu, Xiaohua and Friedrich, Lara Johanna and Efferth, Thomas},
  title = {Natural products targeting tumour angiogenesis},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {10},
  pages = {2094--2136},
  doi = {10.1111/bph.16232}
}
Start for free →